Ipsen: FDA approves indication for Somatuline.
(CercleFinance.com) - Ipsen has announced that the American regulatory authority (FDA) has approved a new indication for Somatuline Depot (lanreotide) 120 mg injection for the treatment of Carcinoid syndrome.
When used, it reduces the frequency of short-acting somatostatin analogue rescue therapy.
Somatuline Depot has already been approved by the FDA to improve survival without progression in patients with gastro-entero-pancreatic neuroendocrine tumors, at locally advanced or metastatic stages, which are unresectable and significantly or moderately differentiated.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
When used, it reduces the frequency of short-acting somatostatin analogue rescue therapy.
Somatuline Depot has already been approved by the FDA to improve survival without progression in patients with gastro-entero-pancreatic neuroendocrine tumors, at locally advanced or metastatic stages, which are unresectable and significantly or moderately differentiated.
Copyright (c) 2017 CercleFinance.com. All rights reserved.